StockData
Roivant Sciences Ltd. logo

Roivant Sciences Ltd.

ROIVNasdaqPharmaceutical PreparationsFiscal year ends March 31
Financials through Q1 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$38.73+0.02 (+0.05%)

Close on Nov 18, 2026Market cap $27.98BP/E –Yield –

Roivant Sciences Total Program-Specific R&D Expense by Quarter

Total Program-Specific R&D Expense ($M)

Periods

Roivant Sciences Total Program-Specific R&D Expense: $96.8M in Q2 FY2026, down 6.2% from a year earlier.

Latest, Q2 FY2026
96.8
Period ended Sep 30, 2026 (CQ3 2026)
Change on a year earlier
-6.2%
103 in Q2 FY2025
History
20 quarters
Since Q1 FY2020
Sources
17
Documents cited below

Where the Q2 FY2026 figure comes from

“|| Total program-specific costs | 96,817 | 103,230 | (6,413)”

Source: Form 10-Q (roiv-20260930.htm, filed 2026-11-09) ↗

Reported in Form 10-K / 10-Q (MD&A & Segment Footnote).

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedTotal Program-Specific R&D Expense ($M)Year on yearSource
Q2 FY2026CQ3 2026Sep 30, 202696.8-6.2%Form 10-Q (roiv-20260930.htm, filed 2026-11-09) ↗
Q1 FY2026CQ2 2026Jun 30, 2026139+55.1%Form 10-Q (roiv-20260630.htm, filed 2026-08-06) ↗
Q3 FY2025CQ4 2025Dec 31, 202595.1+13.5%Form 10-Q (roiv-20251231.htm, filed 2026-02-06) ↗
Q2 FY2025CQ3 2025Sep 30, 2025103+14.7%Form 10-Q (roiv-20250930.htm, filed 2025-11-10) ↗
Q1 FY2025CQ2 2025Jun 30, 202589.7+16.3%Form 10-Q (ef20050394_10q.htm, filed 2025-08-11) ↗
Q3 FY2024CQ4 2024Dec 31, 202483.8+23.7%Form 10-Q (ef20039028_10q.htm, filed 2025-02-10) ↗
Q2 FY2024CQ3 2024Sep 30, 202490.0+9.1%Form 10-Q (ef20034554_10q.htm, filed 2024-11-12) ↗
Q1 FY2024CQ2 2024Jun 30, 202477.1+6.0%Form 10-Q (ef20030921_10q.htm, filed 2024-08-09) ↗
Q3 FY2023CQ4 2023Dec 31, 202367.8-12.8%Form 10-Q (ef20015327_10q.htm, filed 2024-02-13) ↗
Q2 FY2023CQ3 2023Sep 30, 202382.5+1.4%Form 10-Q (ef20012491_10q.htm, filed 2023-11-13) ↗
Q1 FY2023CQ2 2023Jun 30, 202372.7-9.7%Form 10-Q (brhc20057263_10q.htm, filed 2023-08-14) ↗
Q3 FY2022CQ4 2022Dec 31, 202277.7-11.4%Form 10-Q (brhc10047697_10q.htm, filed 2023-02-13) ↗
Q2 FY2022CQ3 2022Sep 30, 202281.4-27.7%Form 10-Q (brhc10044005_10q.htm, filed 2022-11-14) ↗
Q1 FY2022CQ2 2022Jun 30, 202280.5+67.7%Form 10-Q (d383218d10q.htm, filed 2022-08-15) ↗
Q3 FY2021CQ4 2021Dec 31, 202187.7+125.5%Form 10-Q (d12341d10q.htm, filed 2022-02-14) ↗
Q2 FY2021CQ3 2021Sep 30, 2021113+192.7%Form 10-Q (d203748d10q.htm, filed 2021-11-15) ↗

Breakdown

What makes up total Program-Specific R&D Expense

Cite this data

StockData. (2026). Roivant Sciences Total Program-Specific R&D Expense ($M), quarterly Q1 FY2020–Q2 FY2026 [Data set]. Compiled from Roivant Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/roiv/kpis/rd-program-total

See every metric in the Roivant Sciences KPI table. Data updated Nov 16, 2026.

See a number that looks wrong?